Off-label use of maraviroc in clinical practice

Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model

(2015) Jing Yuan et al.   INFLAMMATION RESEARCH

Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression

(2014) Nadejda Beliakova-Bethell et al.   ANTIVIRAL RESEARCH

CCR5 as a Treatment Target in Pulmonary Arterial Hypertension

(2014) Valérie Amsellem et al.   CIRCULATION

Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

(2014) L. Perez-Martinez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

(2014) Lishomwa C. Ndhlovu et al.   JOURNAL OF NEUROVIROLOGY

The Inflammatory Chemokine CCL5 and Cancer Progression

(2014) Donatella Aldinucci et al.   MEDIATORS OF INFLAMMATION

We need a global system to help identify new uses for existing drugs

(2014) R. Borges   BMJ-British Medical Journal

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1

(2013) David A. Cooper et al.   AIDS

Entry inhibitors and their use in the treatment of HIV-1 infection

(2013) Aiman A. Haqqani et al.   ANTIVIRAL RESEARCH

Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice

(2013) Sabrina Cipriani et al.   CIRCULATION

Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice

(2013) Neta Barashi et al.   HEPATOLOGY

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

(2013) Laura Ochoa-Callejero et al.   PLoS One

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

(2012) Ran Reshef et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

(2012) Dona L Fleishaker et al.   ARTHRITIS RESEARCH & THERAPY

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

(2010) Samuel Frank   Neuropsychiatric Disease and Treatment

Chemokines and Cardiovascular Risk

(2008) Pål Aukrust et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY